Y-mAbs Therapeutics (YMAB) to Release Quarterly Earnings on Tuesday

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) will be issuing its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Y-mAbs Therapeutics has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company's conference call can do so using this link.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. The company had revenue of $23.36 million for the quarter, compared to the consensus estimate of $21.72 million. On average, analysts expect Y-mAbs Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB traded down $0.29 on Tuesday, hitting $15.21. The company's stock had a trading volume of 214,271 shares, compared to its average volume of 394,038. The company has a market capitalization of $665.89 million, a price-to-earnings ratio of -31.63 and a beta of 0.74. The stock has a 50 day moving average of $15.72 and a 200-day moving average of $10.65. Y-mAbs Therapeutics has a 12-month low of $4.60 and a 12-month high of $20.90.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on YMAB. Wedbush reissued an "outperform" rating and set a $18.00 price objective (up previously from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. HC Wainwright upped their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Wednesday, March 6th. BMO Capital Markets upped their price objective on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an "outperform" rating in a research note on Monday, March 4th. Finally, Canaccord Genuity Group upped their price target on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a research report on Monday, March 4th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $16.57.

Insider Buying and Selling

In other news, SVP Vignesh Rajah sold 1,711 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total value of $28,282.83. Following the completion of the sale, the senior vice president now owns 33,889 shares of the company's stock, valued at $560,185.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 21.50% of the stock is currently owned by company insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.